|Bid||992.00 x 16300|
|Ask||1,290.00 x 34600|
|Day's range||1,047.00 - 1,118.00|
|52-week range||906.50 - 2,346.00|
|PE ratio (TTM)||15.25|
|Forward dividend & yield||0.22 (1.44%)|
|1y target est||N/A|
MILAN/LONDON, Nov 9 (Reuters) - European shares fell on Thursday as a series of underwhelming earning updates, including from industrial giant Siemens, prompted investors to take profits out of a market still trading near two-year highs. The pan-European STOXX 600 benchmark index fell 1.1 percent, suffering its biggest daily loss since end-June, while Germany's DAX fell 1.5 percent. The STOXX 600 is up 7.9 percent so far this year following a rally that has been fuelled by a combination of strong economic data, solid earnings and easing political fears.
Blue-chip stocks in the U.K. declined Thursday, as house builders fell following soft industry figures and as Burberry shares tumbled the most in more than five years after a disappointing earnings report ...
Harvey Jones says these FTSE 250 (INDEXFTSE:MCX) stocks could reward further investigation despite patchy results.
A drop in luxury group Burberry weighed on the UK's top share index on Thursday, which was stuck below a five-month high as results were the main focus. Britain's blue-chip FTSE 100 index was flat in percentage ...
The dispute between the Jordan-based firm, its partner Vectura (VEC.L) and the U.S FDA delays any eventual approval of the generic version of the drug. Shares of Hikma were down 5.5 percent at market open, while Vectura shares were down about 10 percent.
Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline (Other OTC: GLAXF - news) 's popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time. The dispute between the Jordan-based firm, its partner Vectura and the U.S FDA delays any eventual approval of the generic version of the drug. Shares (Berlin: DI6.BE - news) of Hikma were down 5.5 percent at market open, while Vectura shares were down about 10 percent.
LONDON (Reuters) - Hikma (HIK.L) and its partner Vectura (VEC.L) are in dispute with the Food and Drug Administration over their plans to launch a generic copy of GlaxoSmithKline's (GSK.L) popular lung ...
Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) on Thursday lowered 2017 revenue guidance for its generics business for a third time. The Jordan-based firm, which makes and markets branded and non-branded generic and injectable drugs, said it expected revenue of around $600 million and a core operating margin in the low single-digits from its generics business. In August it had lowered its generics revenue guidance by $50 million to about $620 million, having slashed it to $670 million from an initial $800 million last November.
** Hikma Pharmaceuticals attempts bounce after steep losses since last week's half-year report, up as much as 3.9 pct, but these now almost erased ** Morgan Stanley cuts TP to 1350p from 1600p, Peel Hunt ...
Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) 's U.S. subsidiary has raised the price of a common diarrhea drug by more than 400 percent and is charging more for five other medicines as well, the Financial Times reported on Sunday. West-Ward Pharmaceuticals, the U.S. division of London-listed Hikma, increased the prices at the start of August by between 75 percent and 430 percent, for a mean of 237 percent, according to figures seen by the Financial Times. Among the six drugs, West-Ward is either the only U.S. supplier or one of two manufacturers.
Banks wilting on the prospect of slower U.S. rate hikes dented Britain's major share index on Thursday, and Kingfisher also weighed after a weaker quarterly sales performance. The FTSE 100 fell 0.6 percent, ...
Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) on Thursday said 2017 revenue would be at the lower end of its forecasts, citing increased pricing pressures in the generic drug industry, sending its shares to a more than three-year low. The company had already cut its full-year guidance in May to the range of $2 billion-$2.1 billion at constant currency from $2.2 billion. "Price erosion by the entire generics industry has been significant," Brian Hoffmann, president of the company's U.S. generics business told Reuters.
Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) said on Thursday it expected 2017 revenue at the lower end of its guidance, after increased competition in the generics business hit prices and volumes. The Jordan-based company, which makes and markets branded and non-branded generic and injectable drugs, said it now expected 2017 revenue to be about $2 billion, at the lower end of its previous forecast of $2 billion-$2.1 billion. In May, London-listed Hikma cut full-year guidance for the first time to the range of $2 billion-$2.1 billion at constant currency, down from $2.2 billion.
The FTSE 100 was up nearly 0.5 percent on the day, bringing it into positive territory for the week after its performance was dented by worries over turmoil in U.S. President Donald Trump's administration that sent stocks tumbling across the globe. Investors looked through the political uncertainty to a better earnings season and improved UK retail sales data which pointed to a brighter outlook for consumer-facing stocks.
Britain's major share index recovered on Friday after a pullback in the previous session, marching towards its fourth straight week of gains as investors focused on underlying earnings growth and better ...
European shares rose on Friday, timidly recovering from heavy losses suffered this week after political turmoil fuelled worries over U.S. President Donald Trump's stimulus plans, denting appetite for riskier ...